

REMARKS

Favorable reconsideration is respectfully requested in view of the foregoing amendments and following remarks.

Claims 1-13 have been amended so as to be directed to the method of improving excretory potency of an urinary bladder. Support is found in original claim 19.

Claim 17 was indicated by the Examiner to be allowable if rewritten in independent form. However, claim 17 is independent form. Hence claim 17 is believed to be in condition for allowance in its present form.

Claim 20 was indicated by the Examiner to be allowable if rewritten in independent form. Claim 20 has accordingly been rewritten in independent form. Thus claim 20 is believed to be allowable.

Applicants acknowledge with thanks the Examiner's indication that claims 26-30 and 34 are allowed.

Rejoinder of claims 31-33 is respectfully solicited.

In view of the foregoing amendments, it is believed that each ground of rejection set forth in the Official Action have been overcome.

The rejection under 35 USC 102 as being anticipated by USP5,864,039 to Kawakita et al. is based on the Examiner's misunderstanding. The cited reference discloses benzamide derivatives (ArCO-NH-C-), while the compound of this invention are aromatic ketone derivatives (ArCO-C-). The chemical structure of the compound of the present application is quite different from that of the cited reference.

All other grounds of rejection are deemed to be overcome by the foregoing amendments. The cited references fail to disclose or suggest a method of improving excretory potency of an urinary bladder by administering the compounds according to claims 1-13.

Favorable reconsideration and allowance is respectfully solicited.

Respectfully submitted,

Yuji ISHIHARA et al.

By: Warren M. Cheek, Jr.
Warren M. Cheek, Jr.
Registration No. 33,367
Attorney for Applicants

WMC/dlk
Washington, D.C. 20006-1021
Telephone (202) 721-8200
Facsimile (202) 721-8250
September 30, 2003